CymitQuimica logo

CAS 1787294-07-8

:

Remibrutinib

Description:
Remibrutinib is a small molecule inhibitor that selectively targets Bruton's tyrosine kinase (BTK), an important enzyme in the signaling pathways of B cells. This compound is primarily investigated for its potential therapeutic applications in treating various B cell malignancies and autoimmune diseases. Remibrutinib exhibits high specificity for BTK, which minimizes off-target effects and enhances its efficacy in clinical settings. The chemical structure of Remibrutinib includes functional groups that contribute to its binding affinity and pharmacokinetic properties. It is typically administered orally and has been evaluated in clinical trials for its safety and effectiveness. As with many targeted therapies, the development of Remibrutinib aims to provide a more precise treatment option, potentially leading to improved patient outcomes with fewer side effects compared to traditional chemotherapy. Ongoing research continues to explore its full therapeutic potential and mechanisms of action within the immune system.
Synonyms:
  • REMIBRUTINIB
  • N-(3-{5-[2-(Acryloyl-methyl-amino)-ethoxy]-6-amino-pyrimidin-4-yl}-5-fluoro-2-methyl-phenyl)-4-cyclopropyl-2-fluoro-benzamide
  • Benzamide, N-[3-[6-amino-5-[2-[methyl(1-oxo-2-propen-1-yl)amino]ethoxy]-4-pyrimidinyl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluoro-
  • LOU-064
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 5 products.